Navigation Links
Delpor Announces Issuance of US Patent Covering its Novel Implantable Device for the Long-Term Delivery of Antipsychotics and other Drugs
Date:3/7/2017

Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced that the United States Patent and Trademark Office issued on February 7, 2017 U.S. Patent No. 9,561,352 covering Delpor’s implantable device for the long-term delivery of therapeutic agents. The device uses Delpor’s proprietary PROZOR™ technology for the sustained release of drugs for several months after subcutaneous implantation. Delpor has several product candidates in development, including a 6-month formulation of risperidone and a 3-month formulation of olanzapine, that are covered by the newly issued patent.

Numerous therapeutic agents including risperidone, olanzapine, asenapine, and other CNS molecules can benefit from long-term sustained delivery. The benefits of such delivery include improved medication adherence, as well as a “smooth” pharmacokinetic profile resulting in enhanced safety and tolerability. Most CNS drugs, as well as other important classes, exhibit poor water solubility at neutral pH, creating challenges to the development of implantable sustained delivery systems which rely on passive diffusion as the primary drug release mechanism. Delpor’s proprietary PROZOR technology enables the release of antipsychotics and other agents for several months through passive diffusion, based on a unique formulation. Furthermore, Delpor’s drug delivery implant device, offers full reversibility if treatment discontinuation is needed due to adverse events.

“The issuance of this patent recognizes the novelty of the underlying technology and marks the beginning of a new family of patents for Delpor, making it a key component of our intellectual property portfolio,” said Tassos Nicolaou, President and CEO of Delpor. “The PROZOR technology overcomes the solubility challenges faced by most CNS drugs, and creates the potential for several sustained release long acting therapeutic products, lasting as long as one year. Our lead risperidone program is currently utilizing this unique approach to create a 6-month formulation of the drug which should result in superior clinical outcomes through improved medication adherence.”

Tassos Nicolaou continued: “If treatment discontinuation is needed due to adverse events, the implant can be easily removed by a healthcare professional, and drug plasma levels drop to zero within a day. Our goal is to further expand the use of this innovative platform for the delivery of other agents including the antipsychotics olanzapine and asenapine”

About Delpor, Inc.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company’s technologies enable the sustained release of drugs through a small non-mechanical subcutaneous implant device. The device is implanted during a 10 minute, simple, in-office, procedure using local anesthetic. Delpor’s device can deliver small & large molecules over several months while maintaining zero-order release pharmacokinetics. The company’s lead products include 3-6 month formulations of Risperidone and Exenatide. Additional information about the company can be found at http://www.delpor.com.

About PROZOR™
Delpor’s PROZOR technology enables the sustained release of certain insoluble drugs (including most antipsychotics) from a non-mechanical (passive) implantable drug delivery device based on a unique formulation. A typical formulation is a mixture of the drug and a group of excipients designed to regulate the pH over time. The formulation is in the form of an aqueous suspension held within a small cylindrical reservoir fitted at each end with conventional membranes.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Read the full story at http://www.prweb.com/releases/DelporUSPatentIssuance/032017/prweb14124829.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Isabel Healthcare Announces Integration of American Academy of Pediatrics (AAP) Pediatric Care Online™ (PCO) Resources with Isabel Professional
2. Pearson Announces Career Exploration Mentorship Program for Students, Young Professionals with Disabilities
3. CUBA Beverage Company Announces the Launch of New 100% Natural Alkaline Water Product
4. Alliance Healthcare Foundation Announces 26 Recipients of 2017 Mission Support Grant Program
5. OrthAlign, Inc. Announces Full Commercial Launch of UniAlign™, the World’s First Handheld Navigation Device for Use in Unicompartmental Knee Arthroplasty
6. Pearson Announces SXSWedu Conference 2017 Lineup
7. MyTrimLine Announces, Good Day PA to Use Nadia as the Show’s Nutritional Consultant
8. Fiberstar Announces Winners of the Citri-Fi® 125 Citrus Fiber Student Innovation Contest Supporting the Food and Beverage Industry
9. GAO RFID Announces a New Long Range Personnel Tracking System
10. Aloria Health Announces Opening Of Residential Services
11. ACMA Announces New Release of Compass Directional Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2018)... MALVERN, Pa. (PRWEB) , ... December 06, 2018 ... ... today announced the launch of the Post-Acute Care Symposium (PACS). The meeting will ... Advanced Wound Care (SAWC) Spring/Wound Healing Society meeting in San Antonio, Texas. , ...
(Date:12/5/2018)... ... December 05, 2018 , ... Adam Devlin , co-founder ... to serve on Philadelphia Mayor James F. Kenney’s Commission on People with Disabilities. ... with a cognitive or physical disability. Devlin serves as the chair of the ...
(Date:12/5/2018)... ... , ... Marking its seventh year, Pacifica Graduate Institute Alumni Association (PGIAA) ... World” on New Year’s Eve. Each year event organizer and Director of Alumni ... staff, families, and friends of the institution) to join the celebration. , ...
(Date:12/5/2018)... ... December 05, 2018 , ... Northcentral University (NCU) has ... nursing. Available starting today and on a weekly rolling basis to registered nurses, the ... Practice in Executive Leadership (DNP) will prepare degree candidates to become leaders in ...
(Date:12/5/2018)... , ... December 05, 2018 , ... ... reinforces the theme of Unitek’s transformative conference at the DoubleTree Hilton Hotel in ... LL (AAN), Distinguished Professor and Founder/Director of Watson Caring Science Institute, participants and ...
Breaking Medicine News(10 mins):
(Date:12/5/2018)... ... December 04, 2018 , ... The inaugural Steven Schroeder Award for ... Virginia Mason Health System in Seattle, Washington, at The Leapfrog Group ’s annual ... Costs of Care , a leading non-profit dedicated to curating and disseminating insights from ...
(Date:12/5/2018)... ... December 05, 2018 , ... Two women with a ... Sanford Lorraine Cross Award. , Jean Bennett, M.D., Ph.D., and Katherine A. High, ... accepted the award on Dec. 4 at Sanford Health, headquartered in Sioux Falls, South ...
(Date:11/29/2018)... ... November 29, 2018 , ... Cantata Health, a leading ... for acute care, post-acute care, and long-term care facilities, announced today Elvira Hynds, ... will lead Cantata Health’s highly regarded customer support team focusing on initiatives to ...
Breaking Medicine Technology: